Horsetalk.co.nz - Full Article
August 2, 2017
A rider from Bahrain has been suspended from competition for six months and fined 2000 Swiss francs after his endurance mount tested positive to five substances not permitted under FEI equine anti-doping rules.
The Bahrain-registered horse Ultreia Larzac, ridden by Othman Abduljaleel Al Awadhi, competed in the CEI2* 120km ride at the Bahrain International Endurance Village, Sakhir, on January 14 this year.
The horse was selected for drug testing. The blood sample revealed the presence of caffeine, theophylline, phenylbutazone, oxyphenbutazone, and dexamethasone.
Caffeine is a central nervous system stimulant. Theophylline is used to open airways in the treatment of respiratory disease. Phenylbutazone and its metabolic byproduct oxyphenbutazone are non-steroidal anti-inflammatory drugs with painkilling effects. Dexamethasone is a corticosteroid drug with anti-inflammatory effects...
Read more at https://www.horsetalk.co.nz/2017/08/02/rider-bahrain-suspension-fine-endurance-horse/#OoSjzXMdLBQybC4j.99
Thursday, August 03, 2017
Rider from Bahrain suspended and fined over endurance horse’s positive drug test
Custodian of Two Holy Mosques Endurance Cup 2023 proves AlUla’s credentials as world-class equestrian destination
Plans for a new cutting-edge permanent equestrian location confirmed post event Activities build on area’s rich heritage, improving infrast...
Inside.fei.org 17 December 2020 The FEI Board took a series of key decisions on allocation, cancellation, and reopening of bids for FEI C...
Inside.fei.org 22 June 2022 Author: FEI Communications The FEI Board allocated major FEI Finals and Championships during its two-day in-...
ElRaidBlog - Full Article January 12, 2021 Gabriel Gamiz [google translate] Today I get the sad news of the death of a great horse «NO...